Gufic Biosciences Announces Special Window for Share Re-lodgement and Dematerialisation
Gufic Biosciences opens a special window for physical share re-lodgement and dematerialisation from February 05, 2026, to February 04, 2027. This applies to securities sold/purchased before April 01, 2019, including previously rejected transfers. Transferred shares will be in demat mode with a one-year lock-in.
This is a routine regulatory compliance announcement regarding a special window for share transfers and dematerialisation. It does not involve any significant corporate actions, financial results, or strategic changes that would have a substantial impact on the company's stock or operations.
The announcement is a procedural update regarding a special window for share transfers and dematerialisation, providing information to shareholders. It does not contain any financial performance data or strategic decisions that would indicate a positive or negative sentiment.
Gufic Biosciences Limited has announced a special window for shareholders to re-lodge transfer deeds related to physical securities and for the dematerialisation of shares. This initiative, in accordance with a SEBI circular dated January 30, 2026, will be open from February 05, 2026, to February 04, 2027.
The special window is available for physical securities sold or purchased before April 01, 2019. It also covers cases where transfer requests were previously submitted but rejected or returned due to deficiencies. Shareholders must submit requests with original certificates, transfer deeds, and all relevant supporting documents. Securities transferred under this window will be credited to the transferee in demat mode only and will be subject to a one-year lock-in period from the date of transfer registration, during which they cannot be transferred, lien-marked, or pledged.
Shareholders can contact the company's Registrar and Transfer Agent, MUFG Intime India Private Limited, or Gufic Biosciences' corporate office for any queries or assistance within the stipulated period. The company urges eligible shareholders to utilize this special window for their benefit.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under share transfer updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.